Molecular target-based cancer therapy: Tyrosine kinase inhibitors

International Journal of Clinical Oncology

Volumn 8, Issue 4, 2003, Pages 207-211

  Tamura, Kenji ^a   Fukuoka, Masahiro ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dual HER inhibitor; Human epidermal growth factor receptor (HER) tyrosine kinase inhibitor; Iressa; Irreversible HER inhibitor; Pan HER inhibitor; Tarceva

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; PACLITAXEL; PELITINIB; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ACNE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; FATIGUE; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; NAUSEA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; ENZYME INHIBITORS; GENES, ERBB; HUMANS; NEOPLASMS; PROTEIN-TYROSINE KINASES;

EID: 0141680278     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-003-0320-1     Document Type: Review

References (19)

1. Druker BJ, Sawyers CL, Kantarjian H, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042
2. Ning S, Laird D, Cherrington JM, et al. (2002) The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157:45-51
3. Yang XD, Jia XC, Corvalan JRF, et al. (2001) Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38:17-23
4. Riese DJ, Stern DF (1998) Specificity within the EGFR family/ErbB receptor family signaling network. Bioassays 20:41-48
5. Klapper LN, Kirschbaum MH, Sela M, et al. (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25-79
6. Sobol RE, Astarita RW, Hofeditz C, et al. (1987) Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst 79:403-407
7. Hsieh CC, Chow KC, Fahn HJ, et al. (1998) Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of the lung. Ann Thorac Surg 66:1159-1163
8. Sugawa N, Ekstrand AJ, James CD, et al. (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87:8602-8606
9. Herbst RS, Maddox AM, Rothenberg ML, et al. (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20:3815-3825
10. Fukuoka M, Yano S, Giaccone G, et al. (2002) Final results from a phase II trial of ZD1839 ("Iressa") for patients with advanced nonsmall cell lung cancer (IDEAL 1) (abstract). Proc Am Soc Clin Oncol 21:298a
11. Kris MG, Natale RB, Herbst RS, et al. (2002) A phase II trial of ZD1839 ("Iressa") in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2) (abstract). Proc Am Soc Clin Oncol 21:292a
12. Giaccone G (2002) A phase III clinical trial of ZD1839 ("Iressa") in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (INTACT 1) (abstract 4). Ann Oncol 13(Suppl 5)
13. Johnson DH (2002) ZD1839 ('Iressa') in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC): results from a phase III trial (INTACT 2) (abstract 468). Ann Oncol 13(Suppl 5)
14. Hidalgo M, Siu LL, Nemunaitis J, et al. (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279
15. Karp DD, Silberman R, Csudae R, et al. (1999) Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors (abstract 1499). Proc Am Soc Clin Oncol 18:388a
16. Perez-Soler R, Chachoua A, Huberman M, et al. (2001) A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced-EGFR-expressing, non-small cell lung cancer (NSCLC) (abstract 1235). Proc Am Soc Clin Oncol 20:310a
17. Garrison MA, Tolcher A, McCreery H, et al. (2001) A phase I and pharmacokinetic study of CI-1033, a pan-erbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors (abstract 283). Proc Am Soc Clin Oncol 20:72a
18. Zinner RG, Nemunaitis JJ, Donato NJ, et al. (2001) A phase I clinical and biomarker study of the novel pan-erbB tyrosine kinase inhibitor, CI-1033 (abstact 566). Proc AACR-NCI-EORTC
19. Murren JR, Papadimitrkopoulou VA, Sizer KC, et al. (2001) A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI-166, a novel tyrosine kinase inhibitor, in patients with advanced cancers (abstract 585). Proc AACR-NCIEORTC